边缘区域淋巴瘤:以系统方法为重点的治疗更新
1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
Hematological oncology
|June 15, 2025
概括
边缘区域淋巴瘤 (MZL) 是一种惰的B细胞淋巴瘤,有三种亚型. 虽然不可治愈,但抗原触发器可以导致回归,新疗法为复发或耐药性疾病提供了希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 边缘区域淋巴瘤 (MZL) 是第二个最常见的惰性B细胞淋巴瘤.
- 它呈现出三种亚型: extranodal (MALT),节点和脏.
- MZL是一种抗原驱动的恶性瘤,在触发器消除后有可能回归.
研究的目的:
- 为了提供边缘区域淋巴瘤 (MZL) 的基础知识.
- 讨论MZL的三个临床亚型.
- 专注于以前未接受过治疗以及复发/耐药MZL患者的治疗方法.
主要方法:
- 对MZL当前治疗模式的审查.
- 对复发性或耐火性MZL新兴疗法的讨论.
- 专注于抗原驱动的性质和治疗策略.
主要成果:
- 目前最先进的治疗方法包括rituximab单疗法和化疗免疫疗法.
- 赞努布鲁丁尼布是一种BTK抑制剂,已被批准用于复发性/耐药性MZL.
- 像CAR-T细胞和双特异性抗体这样的新兴疗法显示出有希望的早期结果.
结论:
- 虽然MZL是惰的,并且通常有很好的预后,但仍然是无法治愈的.
- 患者通常需要在一生中重复治疗以治疗疾病.
- 针对性疗法和免疫疗法的进步正在扩大复发/耐药MZL的治疗选择.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Primary Lymphoid Organs
7.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
7.4K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)